http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107417574-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-03 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-03 |
| filingDate | 2017-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107417574-B |
| titleOfInvention | 2,4- disubstituted benzene ethanone compounds and its optical isomer, pharmaceutically acceptable salt and application |
| abstract | The present invention relates to a kind of 2,4- disubstituted benzene ethanone compounds and its optical isomers, pharmaceutically acceptable salt.The invention also discloses 2, the application of 4- disubstituted benzene ethanone compounds and its optical isomer, pharmaceutically acceptable salt in terms for the treatment of neurodegenerative disease, such noval chemical compound not only has inhibiting activity of acetylcholinesterase and A beta-aggregation rejection ability, its hydrolysate also has chelation of metal ion, it can be treated from multiple target spots, there is preferable neurodegenerative disease application prospect. |
| priorityDate | 2017-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.